Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. / Thulesen, J; Hartmann, B; Hare, K J; Kissow, H; Ørskov, C; Holst, Jens Juul; Poulsen, S S.

In: Gut, Vol. 53, No. 8, 08.2004, p. 1145-1150.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Thulesen, J, Hartmann, B, Hare, KJ, Kissow, H, Ørskov, C, Holst, JJ & Poulsen, SS 2004, 'Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice', Gut, vol. 53, no. 8, pp. 1145-1150. https://doi.org/10.1136/gut.2003.035212

APA

Thulesen, J., Hartmann, B., Hare, K. J., Kissow, H., Ørskov, C., Holst, J. J., & Poulsen, S. S. (2004). Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut, 53(8), 1145-1150. https://doi.org/10.1136/gut.2003.035212

Vancouver

Thulesen J, Hartmann B, Hare KJ, Kissow H, Ørskov C, Holst JJ et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut. 2004 Aug;53(8):1145-1150. https://doi.org/10.1136/gut.2003.035212

Author

Thulesen, J ; Hartmann, B ; Hare, K J ; Kissow, H ; Ørskov, C ; Holst, Jens Juul ; Poulsen, S S. / Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. In: Gut. 2004 ; Vol. 53, No. 8. pp. 1145-1150.

Bibtex

@article{0ea548b9c16d495abf81ec0610a4a2b2,
title = "Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice",
abstract = "BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine.AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.RESULTS: Colonic polyps developed in 100{\%} of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.",
keywords = "Adenoma, Animals, Body Weight, Colonic Neoplasms, Colonic Polyps, Female, Glucagon-Like Peptide 2, Glucagon-Like Peptides, Intestinal Mucosa, Intestine, Small, Mice, Mice, Inbred C57BL, Organ Size, Peptides",
author = "J Thulesen and B Hartmann and Hare, {K J} and H Kissow and C {\O}rskov and Holst, {Jens Juul} and Poulsen, {S S}",
year = "2004",
month = "8",
doi = "10.1136/gut.2003.035212",
language = "English",
volume = "53",
pages = "1145--1150",
journal = "Gut",
issn = "0017-5749",
publisher = "B M J Group",
number = "8",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

AU - Thulesen, J

AU - Hartmann, B

AU - Hare, K J

AU - Kissow, H

AU - Ørskov, C

AU - Holst, Jens Juul

AU - Poulsen, S S

PY - 2004/8

Y1 - 2004/8

N2 - BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine.AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.RESULTS: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.

AB - BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine.AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.RESULTS: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.

KW - Adenoma

KW - Animals

KW - Body Weight

KW - Colonic Neoplasms

KW - Colonic Polyps

KW - Female

KW - Glucagon-Like Peptide 2

KW - Glucagon-Like Peptides

KW - Intestinal Mucosa

KW - Intestine, Small

KW - Mice

KW - Mice, Inbred C57BL

KW - Organ Size

KW - Peptides

U2 - 10.1136/gut.2003.035212

DO - 10.1136/gut.2003.035212

M3 - Journal article

C2 - 15247183

VL - 53

SP - 1145

EP - 1150

JO - Gut

JF - Gut

SN - 0017-5749

IS - 8

ER -

ID: 132054279